CytRx (CYTR) vs. Denali Therapeutics (DNLI) Head-To-Head Analysis

CytRx (NASDAQ: CYTR) and Denali Therapeutics (NASDAQ:DNLI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

6.1% of CytRx shares are held by institutional investors. Comparatively, 61.0% of Denali Therapeutics shares are held by institutional investors. 5.3% of CytRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CytRx and Denali Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytRx N/A -187.35% -65.74%
Denali Therapeutics N/A N/A N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for CytRx and Denali Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytRx 0 0 1 0 3.00
Denali Therapeutics 0 1 3 0 2.75

CytRx currently has a consensus target price of $24.00, indicating a potential upside of 1,438.46%. Denali Therapeutics has a consensus target price of $24.00, indicating a potential upside of 32.52%. Given CytRx’s stronger consensus rating and higher probable upside, analysts plainly believe CytRx is more favorable than Denali Therapeutics.

Valuation and Earnings

This table compares CytRx and Denali Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CytRx $100,000.00 437.42 -$34.98 million N/A N/A
Denali Therapeutics N/A N/A -$88.18 million ($5.89) -3.07

CytRx has higher revenue and earnings than Denali Therapeutics.

Summary

CytRx beats Denali Therapeutics on 5 of the 9 factors compared between the two stocks.

CytRx Company Profile

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Denali Therapeutics Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply